PriceTargets.com logo

BrainsWay - BWAY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 47.99%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.73 As of 04/23/2024 10:30 AM ET
▼ -0.02 (-0.42%)

This chart shows the closing price for BWAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BrainsWay Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BWAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BWAY

Analyst Price Target is $7.00
▲ +47.99% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for BrainsWay in the last 3 months. The average price target is $7.00, with a high forecast of $12.00 and a low forecast of $3.00. The average price target represents a 47.99% upside from the last price of $4.73.

This chart shows the closing price for BWAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 contributing investment analysts is to moderate buy stock in BrainsWay. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/11/2024HC WainwrightReiterated RatingBuyLow
11/16/2023OppenheimerBoost TargetOutperform ➝ Outperform$5.50 ➝ $6.00Low
11/16/2023Raymond JamesDowngradeOutperform ➝ Market PerformLow
9/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
9/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
8/21/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
5/18/2023Raymond JamesLower Target$3.75 ➝ $3.00Low
4/13/2023HC WainwrightLower TargetBuy$13.00 ➝ $12.00Low
2/1/2023HC WainwrightReiterated RatingBuy$13.00Low
12/12/2022HC WainwrightLower TargetBuy$16.00 ➝ $13.00Low
11/21/2022Raymond JamesLower TargetOutperform$8.00 ➝ $3.75Low
11/17/2022Northland SecuritiesLower TargetOutperform$15.00 ➝ $5.00Low
8/22/2022HC WainwrightBoost TargetBuy$15.00 ➝ $16.00Low
8/11/2022Raymond JamesLower TargetOutperform$10.00 ➝ $8.00Low
7/5/2022HC WainwrightReiterated RatingBuy$15.00N/A
3/3/2022Loop CapitalInitiated CoverageBuy$15.00High
11/29/2021HC WainwrightBoost TargetBuy$14.00 ➝ $15.00Medium
11/17/2021LADENBURG THALM/SH SHBoost TargetBuy$16.00 ➝ $17.00Low
10/1/2021HC WainwrightReiterated RatingBuy$14.00Low
9/2/2021HC WainwrightReiterated RatingBuy$14.00Low
8/12/2021HC WainwrightLower TargetBuy$17.00 ➝ $14.00Low
7/19/2021HC WainwrightInitiated CoverageBuy$17.00High
5/21/2021OppenheimerReiterated RatingBuy$15.00Medium
4/20/2021Northland SecuritiesInitiated CoverageOutperform$15.00High
3/26/2021OppenheimerBoost TargetOutperform$13.00 ➝ $15.00High
2/17/2021Raymond JamesBoost TargetOutperform$9.00 ➝ $12.00Low
9/22/2020OppenheimerInitiated CoverageBuy$13.00Medium
8/14/2020Cantor FitzgeraldReiterated RatingBuy$13.00Low
8/13/2020Raymond JamesLower TargetOutperform$10.00 ➝ $9.00Medium
7/14/2020Cantor FitzgeraldReiterated RatingOverweight$10.00Low
6/24/2020OppenheimerReiterated RatingBuy$13.00Low
3/24/2020Raymond JamesLower TargetOutperform$13.00 ➝ $9.00High
3/24/2020Cantor FitzgeraldLower TargetOverweight$17.00 ➝ $13.00High
11/26/2019Raymond JamesLower TargetOutperform$14.00 ➝ $13.00High
5/13/2019CIBCInitiated CoverageOutperform ➝ OutperformHigh
5/13/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$14.00High
5/13/2019OppenheimerInitiated CoverageOutperform$17.00High
5/13/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$19.00High
5/13/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$17.00High
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.88 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

BrainsWay logo
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: $4.73
Low: $4.73
High: $4.73

50 Day Range

MA: $5.82
Low: $4.74
High: $7.14

52 Week Range

Now: $4.73
Low: $1.38
High: $7.61

Volume

1,475 shs

Average Volume

120,708 shs

Market Capitalization

$78.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of BrainsWay?

The following Wall Street analysts have issued reports on BrainsWay in the last year: HC Wainwright, Oppenheimer Holdings Inc., and Raymond James.
View the latest analyst ratings for BWAY.

What is the current price target for BrainsWay?

3 Wall Street analysts have set twelve-month price targets for BrainsWay in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 47.7%. HC Wainwright has the highest price target set, predicting BWAY will reach $12.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $3.00 for BrainsWay in the next year.
View the latest price targets for BWAY.

What is the current consensus analyst rating for BrainsWay?

BrainsWay currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BWAY.

What other companies compete with BrainsWay?

Other companies that are similar to BrainsWay include Monogram Orthopaedics, BlueRiver Acquisition, KORU Medical Systems, enVVeno Medical and IceCure Medical. Learn More about companies similar to BrainsWay.

How do I contact BrainsWay's investor relations team?

BrainsWay's physical mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company's listed phone number is (722) 582-4030 and its investor relations email address is [email protected]. The official website for BrainsWay is www.brainsway.com. Learn More about contacing BrainsWay investor relations.